Skip to main content

Table 1 Baseline patient characteristics according to the expression level of HSPA8 in TCGA CN-AML patients

From: High HSPA8 expression predicts adverse outcomes of acute myeloid leukemia

Group Cohort P
HSPA8high HSPA8low
Total 38 39  
Age
 ≥ 60y 22 20 0.649
 < 60y 16 19  
Sex
 Male 18 24 0.256
 Female 20 15  
FAB classification
 M0 0 6 0.036
 M1 13 7 0.172
 M2 13 7 0.172
 M3 0 0 0.999
 M4 4 15 0.01
 M5 7 3 0.289
 M6 0 1 0.999
 M7 1 0 0.999
Clinical characteristics (mean(SD))
 BM blast (%) 42.84(33.17) 38.87(20.43) 0.792
 WBC (×10^9) 36.62(36.52) 46.21(48.25) 0.334
 Hemoglobin (g/L) 9.47(1.62) 9.92(1.35) 0.2
 Platelet (×10^9) 80.46(66.98) 66.47(48.11) 0.303
Mutation
FLT3 22 5 < 0.0001
IDH1 7 13 0.194
IDH2 4 8 0.227
KRAS 2 1 0.982
CEBPA 4 4 0.999
TET2 5 3 0.68
TP53 1 0 0.99
NRAS 2 2 0.999
RUNX1 2 9 0.056
NPM1 16 22 0.301
  1. FAB French-American-British classification